AbbVie Acquires Nimble Therapeutics in $200 Million Deal

NextCure and Avere Therapeutics Announce Merger and $320 Million Financing to Create Oral IL-23 Biotech

July 17, 2026

Biotechnology

NextCure and Avere Therapeutics have entered into a definitive all-stock merger that will create a publicly traded biotechnology company focused on developing once-weekly oral therapies for inflammatory diseases driven by interleukin-23. The transaction is supported by a concurrent $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group to fund key clinical milestones through Phase 2b and into Phase 3 development.

AbbVie Acquires Apogee Therapeutics for $10.9 Billion

June 22, 2026

Biotechnology

AbbVie entered into a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion ($135.11 per share). The deal is intended to deepen AbbVie’s immunology portfolio and expand its clinical presence in respiratory diseases, with Apogee’s lead program zurilokibart (APG777) targeting IL-13 for atopic dermatitis and its pipeline including APG273 for asthma. Closing was expected in Q3 2026, subject to customary regulatory and shareholder approvals; AbbVie later announced completion on Sept. 3, 2026.

AbbVie Acquires Celsius Therapeutics

June 27, 2024

Biotechnology

AbbVie has acquired Celsius Therapeutics, a Cambridge-based clinical-stage biotechnology company, for $250 million in cash. The acquisition adds Celsius' lead anti-TREM1 antibody candidate CEL383 to AbbVie’s inflammatory disease pipeline to support development for inflammatory bowel disease (IBD).

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Pharmaceuticals

AbbVie (AbbVie Inc.) announced it will acquire Cerevel Therapeutics in a definitive agreement, strengthening its neuroscience pipeline with multiple clinical- and preclinical-stage programs. The deal values Cerevel at about $8.7 billion and is structured as an all-cash purchase of all outstanding Cerevel shares for $45.00 per share.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Pharmaceuticals

AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.